Local gene therapy of solid tumors with GM-CSF and B7-1 eradicates both treated and distal tumors
Open Access
- 28 July 2006
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 13 (12) , 1061-1071
- https://doi.org/10.1038/sj.cgt.7700976
Abstract
Gene therapy-induced expression of immunostimulatory molecules at tumor cell level may evoke antitumor immune mechanisms by recruiting and enhancing viability of antigen-processing cells and specific tumoricidal lymphocytes. The antitumor efficacy of a plasmid, coding for granulocyte–macrophage colony-stimulating factor (GM-CSF) and the B7-1 costimulatory immune molecule, delivered into growing solid tumors by electroporation was investigated. Murine fibrosarcomas (JBS) growing in Balb/C mice (100 mm3) were transfected with GM-CSF/B7-1-expressing plasmid. Complete tumor regression occurred in greater than 60% of treated animals. This response was systemic, durable and tumor specific, with all responding animals resistant to repeat tumor challenge. Using a liver metastatic model, effective cure of distal metastases was achieved following treatment of the primary subcutaneous tumor. This treatment strategy could be applicable in the clinical setting for effective elimination of both primary tumors and associated metastatic disease.Keywords
This publication has 20 references indexed in Scilit:
- Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumorsThe Journal of Experimental Medicine, 2005
- DNAzyme for TGF-β suppressed extracellular matrix accumulation in experimental glomerulonephritisKidney International, 2004
- The Inflammatory Response Within Dukes' B Colorectal Cancers: Implications for Progression of Micrometastases and Patient SurvivalAmerican Journal of Gastroenterology, 2000
- Tumor cells cotransduced with B7.1 and γ-IFN induce effective rejection of established parental tumorGene Therapy, 1999
- Enhanced Tumor Protection by Granulocyte-Macrophage Colony-Stimulating Factor Expression at the Site of an Allogeneic VaccineHuman Gene Therapy, 1998
- Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte–macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunityGene Therapy, 1998
- T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells.The Journal of Experimental Medicine, 1994
- Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.The Journal of Experimental Medicine, 1994
- The Role of the CD28 Receptor During T Cell Responses to AntigenAnnual Review of Immunology, 1993
- Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4Cell, 1992